Evidence map›Paper›PMID 30612520›Full record

ArticleTissue engineering. Part A2019

CXCR4 Antagonism to Treat Delayed Fracture Healing.

Richard Meeson, Anita Sanghani-Keri, Melanie Coathup, Gordon Blunn

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tissue engineering. Part A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Richard MeesonDivision of Surgery, Institute of Orthopaedics and Musculoskeletal Science, University College London, London, United Kingdom.
Anita Sanghani-KeriDivision of Surgery, Institute of Orthopaedics and Musculoskeletal Science, University College London, London, United Kingdom.
Melanie CoathupDivision of Surgery, Institute of Orthopaedics and Musculoskeletal Science, University College London, London, United Kingdom.
Gordon BlunnDivision of Surgery, Institute of Orthopaedics and Musculoskeletal Science, University College London, London, United Kingdom.
Institute for Musculoskeletal Health · AURoyal Veterinary College · GBUniversity College London · GB

Funding

Medical Research Council MR/N002318/1
6 · The paper itself

Abstract

impact statementCurrently ∼10% of fractures progress to delayed or nonunion with significant morbidity and economic impact. Endogenous mobilization of stem cells by pharmacological antagonism of their homing and migration receptor CXCR4 with AMD3100 experimentally reduced delayed union development. Endogenous mobilization may, therefore, translate as a low risk means to boost healing and could potentially be given as a prophylaxis to patients with fractures at risk of delayed healing or nonunion. These patients may include fragility fractures, comminuted tibial fractures, or when treating established nonunions. This approach could have promise for other conditions that may benefit from stem cell treatments.

Indexed as

AnimalsBenzylaminesCyclamsExternal FixatorsFemaleFracture HealingHeterocyclic CompoundsRatsRats, WistarReceptors, CXCR4Tibial FracturesX-Ray MicrotomographyBenzylaminesCxcr4 protein, ratCyclamsHeterocyclic CompoundsplerixaforReceptors, CXCR4AMD3100CXCR4delayed unionendogenous mobilizationexternal fixatorfracture healing

Identifiers

PMID30612520
PMCPMC6864747
OpenAlexW2907717937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.